Treatment of schizophrenia with ergot derivatives
- 1 December 1979
- journal article
- research article
- Published by Springer Nature in Psychopharmacology
- Vol. 66 (3) , 239-242
- https://doi.org/10.1007/bf00428312
Abstract
Seven neuroleptic-free schizophrenic patients received bromocriptine and eight schizophrenic patients received CF 25-397, both ergot derivatives with dopamine agonist activity. Psychosis failed to improve in response to either drug at the relatively low doses administered. Unlike the antipsychotic property of apomorphine at low dose levels, neither of these ergot drugs improved schizophrenic symptomatology.Keywords
This publication has 20 references indexed in Scilit:
- Bromocriptine and CF 25-397 in the Treatment of Tardive DyskinesiaArchives of Neurology, 1980
- Lergotrile and lisuride: In vivo dopaminergic agonists which do not stimulate the presynaptic dopamine autoreceptorLife Sciences, 1978
- Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitive adenylyl cyclaseLife Sciences, 1978
- Schizophrenic Symptoms Improve with ApomorphineScience, 1978
- Experiences with a new ergoline (CF 25–397) in parkinsonismNeurology, 1977
- Endocrine profile of ergot alkaloidsLife Sciences, 1977
- Developments in the pharmacology and therapeutics of parkinsonismAnnals of Neurology, 1977
- Effects of bromocriptine on central dopaminergic receptorsLife Sciences, 1976
- Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neuronsJournal of Pharmacy and Pharmacology, 1973
- Evidence for a receptor-mediated feedback control of striatal tyrosine hydroxylase activityJournal of Pharmacy and Pharmacology, 1972